TABLE 5.

The protective role of different cannabinoids in skin fibrosis.

Compound	Dose, duration, and route of administration	Mechanisms of protection	Reference
JWH‐133	1,1.5, 2, 2.5, 3, 4 mg/kg, i.p. for 6 weeks to BALB/c Mice	↓collagen ↓dermal thickness	[85]
JWH‐133	2.5 mg/kg, i.p. for 4 weeks to C57BL mice	↓dermal thickness	[86]
JWH‐133	3 μM for 18 hours to human fibroblasts	↓collagen, ↓α‐SMA	[87]
EHP‐101	5, 10, and 25 mg/kg, p.o. for 3 weeks to BALB/c mice	↓collagen, ↓Tenascin, ↓VCAM, ↓Vimentin	[69]
VCE‐004.3	20 mg/kg, i.p. for 6 weeks to BALB/C mice	↓collagen, ↓F4/80+ ↓SMAD2/SMAD3 ↓ERK1/2, ↓CD3+, ↓ macrophages	[83]
VCE‐004.8	10, 20 mg/kg, i.p. for 3 weeks to BALB/c mice	↓Smad2/Smad3 ↓F4/80+, ↓Col3A1, Col1A2, IL‐1β and IL‐13	[84]
GP1a	3 mg/kg, i.p. BALB/c mic	↓MCP‐1, SDF‐1, TNF‐α and TGF‐β1 ↓L‐6, IL‐1β, and VEGF, ↓collagen	[88]
GP1a	3 mg/kg/day, i.p. BALB/c mice	↓collagen I ↓TGF‐β1, P‐Smad3	[89]
WIN55,212‐2	1 mg/kg/day, s.c. for 21 days to DBA/2 J mice	↓hydroxyproline ↓α‐SMA, ↓PDGF and ↓TGFβ	[90]
WIN55,212‐2	1 and 10 M for 24 days to dermal fibroblasts	↓ collagen I ↓TGF‐ β and CTGF ↓p‐ERK‐1/2	[91]